PL3003039T3 - Związki pirydynonopirydynylowe podstawione metylo/fluoropirydynylometoksylem oraz związki pirydynonopirydynylowe podstawione fluoropirymidynylometoksylem - Google Patents

Związki pirydynonopirydynylowe podstawione metylo/fluoropirydynylometoksylem oraz związki pirydynonopirydynylowe podstawione fluoropirymidynylometoksylem

Info

Publication number: PL3003039T3
Authority: PL; Poland
Prior art keywords: pyridinyl; fluoro; methoxy substituted; compounds; substituted pyridinone
Prior art date: 2013-06-07

Application number

PL14808115T

Other languages

English (en)

Inventor

Susan L. Hockerman

Joseph B. Monahan

Shaun R. Selness

Original Assignee

Aclaris Therapeutics, Inc.

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2013-06-07

Filing date

2014-06-06

Publication date

2021-10-25

2014-06-06 Application filed by Aclaris Therapeutics, Inc. filed Critical Aclaris Therapeutics, Inc.

2021-10-25 Publication of PL3003039T3 publication Critical patent/PL3003039T3/pl

Links

-1 fluoro-pyrimidinyl-methoxy Chemical group 0.000 title 1
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 title 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/62—Oxygen or sulfur atoms
- C07D213/69—Two or more oxygen atoms

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Epidemiology (AREA)
Immunology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Biomedical Technology (AREA)
Diabetes (AREA)
Rheumatology (AREA)
Hematology (AREA)
Dermatology (AREA)
Physical Education & Sports Medicine (AREA)
Pain & Pain Management (AREA)
Orthopedic Medicine & Surgery (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Endocrinology (AREA)
Psychology (AREA)
Oncology (AREA)
Obesity (AREA)
Vascular Medicine (AREA)
Emergency Medicine (AREA)
Transplantation (AREA)
Hospice & Palliative Care (AREA)
Pulmonology (AREA)
Urology & Nephrology (AREA)
Communicable Diseases (AREA)

PL14808115T 2013-06-07 2014-06-06 Związki pirydynonopirydynylowe podstawione metylo/fluoropirydynylometoksylem oraz związki pirydynonopirydynylowe podstawione fluoropirymidynylometoksylem PL3003039T3 (pl)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US201361832736P	2013-06-07	2013-06-07
PCT/US2014/041381 WO2014197846A1 (en)	2013-06-07	2014-06-06	Methyl/fluoro-pyridinyl-methoxy substituted pyridinone-pyridinyl compounds and fluoro-pyrimidinyl-methoxy substituted pyridinone-pyridinyl compounds
EP14808115.1A EP3003039B1 (en)	2013-06-07	2014-06-06	Methyl/fluoro-pyridinyl-methoxy substituted pyridinone-pyridinyl compounds and fluoro-pyrimidinyl-methoxy substituted pyridinone-pyridinyl compounds

Publications (1)

Publication Number	Publication Date
PL3003039T3 true PL3003039T3 (pl)	2021-10-25

Family

ID=52005972

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
PL14808115T PL3003039T3 (pl)	2013-06-07	2014-06-06	Związki pirydynonopirydynylowe podstawione metylo/fluoropirydynylometoksylem oraz związki pirydynonopirydynylowe podstawione fluoropirymidynylometoksylem

Country Status (18)

Country	Link
US (2)	US9115089B2 (pl)
EP (2)	EP3003039B1 (pl)
JP (4)	JP6699909B2 (pl)
KR (3)	KR102313515B1 (pl)
CN (2)	CN105263326B (pl)
CA (1)	CA2917344C (pl)
CY (1)	CY1124222T1 (pl)
DK (1)	DK3003039T3 (pl)
ES (1)	ES2869048T3 (pl)
HR (1)	HRP20210813T1 (pl)
HU (1)	HUE054178T2 (pl)
LT (1)	LT3003039T (pl)
PL (1)	PL3003039T3 (pl)
PT (1)	PT3003039T (pl)
RS (1)	RS61724B1 (pl)
SI (1)	SI3003039T1 (pl)
SM (1)	SMT202100117T1 (pl)
WO (1)	WO2014197846A1 (pl)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CA2917344C (en) *	2013-06-07	2021-09-07	Confluence Life Sciences, Inc.	Methyl/fluoro-pyridinyl-methoxy substituted pyridinone-pyridinyl compounds and fluoro-pyrimidinyl-methoxy substituted pyridinone-pyridinyl compounds
EP3502692A1 (en)	2017-12-20	2019-06-26	Aposcience AG	Potency assay for secretomes
MX2022001151A (es)	2019-07-31	2022-02-22	Aclaris Therapeutics Inc	Inhibidores deuterados de la via mk2 y metodos de uso de los mismos.
BR112022019349A2 (pt) *	2020-03-27	2022-11-16	Aclaris Therapeutics Inc	Forma cristalina, composição farmacêutica, comprimido e método para isolar um composto
EP4247380A4 (en) *	2020-11-23	2025-03-05	Aclaris Therapeutics, Inc.	PROCESSES FOR THE SYNTHESIS OF SUBSTITUTED PYRIDINONE-PYRIDINYL COMPOUNDS
CN116685322A (zh) *	2020-11-23	2023-09-01	阿克拉瑞斯治疗股份有限公司	合成被取代的吡啶酮-吡啶基化合物的方法
IL307187A (en) *	2021-03-31	2023-11-01	Xinthera Inc	MK2 inhibitors and their uses
KR20240035830A (ko) *	2021-07-09	2024-03-18	신테라, 인크.	피리디논 mk2 저해제 및 이의 용도
CN117651698A (zh) *	2021-07-09	2024-03-05	新特拉有限公司	吡啶酮mk2抑制剂及其用途
WO2023001282A1 (zh) *	2021-07-23	2023-01-26	南京明德新药研发有限公司	杂环取代的嘧啶衍生物
TW202315625A (zh) *	2021-08-13	2023-04-16	大陸商深圳信立泰藥業股份有限公司	三聯吡啶二酮化合物或其鹽、包括其藥物組合物及其用途
CN116178345B (zh) *	2021-10-19	2024-08-13	深圳信立泰药业股份有限公司	一种取代的嘧啶基-吡啶基-吡啶酮化合物及其制备方法与应用
TWI836822B (zh) *	2021-12-29	2024-03-21	大陸商上海美悦生物科技發展有限公司	p38 MAPK/MK2通路調節劑及其組合物、製備方法和用途
WO2023125708A1 (zh) *	2021-12-29	2023-07-06	上海美悦生物科技发展有限公司	一种p38 MAPK/MK2通路调节剂及其组合物、制备方法和用途
CN116396274B (zh) *	2022-01-06	2025-11-11	深圳信立泰药业股份有限公司	一种取代的联吡啶酮类化合物及其制备方法与应用
CN116425722B (zh) *	2022-01-13	2025-11-11	深圳信立泰药业股份有限公司	一种取代的联吡啶酮-芳(杂)环类化合物及其制备方法与应用
WO2023134764A1 (zh)	2022-01-14	2023-07-20	上海翰森生物医药科技有限公司	含吡啶多环类衍生物、其制备方法和应用
CN116444493A (zh) *	2022-01-14	2023-07-18	上海翰森生物医药科技有限公司	含双并环类衍生物、其制备方法和应用
US20230286950A1 (en) *	2022-02-04	2023-09-14	Aclaris Therapeutics, Inc.	Methods of synthesizing deuterated substituted pyridinone-pyridinyl compounds
WO2023165554A1 (zh) *	2022-03-03	2023-09-07	深圳信立泰药业股份有限公司	一种氘代三联吡啶二酮化合物或其盐及其制备方法与应用
CN115057811B (zh) *	2022-05-26	2024-06-14	安庆朗坤药业有限公司	一种2-溴甲基-3,5-二氟吡啶的制备方法
WO2024022412A1 (zh) *	2022-07-28	2024-02-01	深圳信立泰药业股份有限公司	一种式(i)所示的三联吡啶二酮化合物晶型及其制备方法与应用
CN119053588A (zh) *	2022-08-30	2024-11-29	长春金赛药业有限责任公司	p38α-MK2抑制剂化合物、药物组合物及其应用
US20240182449A1 (en) *	2022-10-05	2024-06-06	Xinthera, Inc.	Crystalline forms of an mk2 inhibitor
CN118047757A (zh) *	2022-11-16	2024-05-17	上海美悦生物科技发展有限公司	吡啶氮氧化物类衍生物及其药物组合物、制备方法和用途
WO2024149359A1 (zh) *	2023-01-13	2024-07-18	上海美悦生物科技发展有限公司	苯基取代的杂芳基类化合物及其药物组合物、制备方法和用途
CN121368484A (zh) *	2023-06-26	2026-01-20	深圳信立泰药业股份有限公司	一种mk2抑制剂在制备预防和/或治疗疾病药物中的应用
WO2025092739A1 (zh) *	2023-10-30	2025-05-08	浙江星浩澎博医药有限公司	二氢苯并呋喃类衍生物、其制备方法和用途

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US789061A (en) *	1904-07-11	1905-05-02	Harrison G Post	Paper barrel.
JP2002526482A (ja)	1998-09-18	2002-08-20	バーテックスファーマシューティカルズインコーポレイテッド	ｐ３８のインヒビター
SK16482001A3 (sk)	1999-05-21	2002-04-04	Scios Inc.	Indolové deriváty ako inhibítory p38 kinázy
WO2002042292A2 (en)	2000-11-20	2002-05-30	Scios Inc.	Indol derivative and their use as inhibitors of p38 kinase
US7314752B2 (en)	2001-07-19	2008-01-01	Common Sense, Ltd.	Secretion-monitoring article
ES2334990T3 (es)	2002-02-14	2010-03-18	Pharmacia Corporation	Piridinonas sustituidas como moduladores de p38 map quinasa.
AU2003237121A1 (en)	2002-04-26	2003-11-10	Vertex Pharmaceuticals Incorporated	Pyrrole derivatives as inhibitors of erk2 and uses thereof
GB0218630D0 (en)	2002-08-10	2002-09-18	Tanabe Seiyaku Co	Novel compounds
US7517532B2 (en)	2002-09-11	2009-04-14	Merck & Co., Inc.	Dihydroxypyridopyrazine-1,6-dione compounds useful as HIV integrase inhibitors
US7183287B2 (en)	2003-04-03	2007-02-27	Pharmacia Corporation	Substituted pyrimidinones
US20070167621A1 (en)	2003-04-03	2007-07-19	Pharmacia Corporation	Substituted pyrimidinones
NL1026826C2 (nl)	2003-08-13	2007-01-04	Pharmacia Corp	Gesubstitueerde pyridinonen.
JP2005255675A (ja)	2004-02-09	2005-09-22	Tanabe Seiyaku Co Ltd	医薬組成物
EP1720856B1 (en)	2004-02-11	2013-08-14	GlaxoSmithKline LLC	Hiv integrase inhibitors
US7576212B2 (en) *	2004-12-09	2009-08-18	Xention Limited	Thieno[2,3-B] pyridines as potassium channel inhibitors
JPWO2006109876A1 (ja)	2005-04-08	2008-11-20	エーザイ・アール・アンド・ディー・マネジメント株式会社	不随意運動治療剤
TW200740755A (en)	2005-07-13	2007-11-01	Bayer Cropscience Sa	Dihalogenation of N,O-disubstituted hydroxypyridones and their uses
WO2007081901A2 (en)	2006-01-05	2007-07-19	The Scripps Research Institute	Pyrimidinone derivatives as protein kinase inhibitors
PE20080150A1 (es)	2006-06-02	2008-04-11	Janssen Pharmaceutica Nv	Derivados de piridinona n-aril y n-heteroaril sustituidos como antagonistas del receptor de la hormona concentradora de melanina (mch)
EP2049115B1 (en)	2006-07-14	2013-08-21	Amgen Inc.	Alkyne-substituted pyridone compounds and methods of use
EP2256115A1 (en)	2006-11-24	2010-12-01	Takeda Pharmaceutical Company Limited	Heteromonocyclic compound and use thereof
KR20090086582A (ko)	2006-12-07	2009-08-13	노파르티스 아게	유기 화합물
CA2689607A1 (en)	2007-06-06	2008-12-18	Tyrogenex, Inc.	Kinase inhibitor compounds
TW200904440A (en)	2007-07-17	2009-02-01	Bristol Myers Squibb Co	Method for modulating GPR119 G protein-coupled receptor and selected compounds
MX2010014572A (es)	2008-06-27	2011-03-24	Novartis Ag	Compuestos organicos.
WO2011003007A1 (en)	2009-07-01	2011-01-06	Albany Molecular Research, Inc.	Azabicycloalkane-indole and azabicycloalkane-pyrrolo-pyridine mch-1 antagonists, methods of making, and use thereof
WO2011003012A1 (en)	2009-07-01	2011-01-06	Albany Molecular Research, Inc.	Azinone-substituted azapolycycle mch-1 antagonists, methods of making, and use thereof
US9073925B2 (en)	2009-07-01	2015-07-07	Albany Molecular Research, Inc.	Azinone-substituted azabicycloalkane-indole and azabicycloalkane-pyrrolo-pyridine MCH-1 antagonists, methods of making, and use thereof
CA2819889C (en)	2010-12-06	2020-12-15	Confluence Life Sciences, Inc.	Substituted pyridinone-pyridinyl compounds
US9056110B2 (en) *	2011-12-06	2015-06-16	Confluence Life Sciences, Inc.	Substituted pyrimidinone-phenyl-pyrimidinyl compounds
CA2917344C (en) *	2013-06-07	2021-09-07	Confluence Life Sciences, Inc.	Methyl/fluoro-pyridinyl-methoxy substituted pyridinone-pyridinyl compounds and fluoro-pyrimidinyl-methoxy substituted pyridinone-pyridinyl compounds
USD789061S1 (en) *	2015-11-04	2017-06-13	Salomon S.A.S.	Upper of a footwear article

2014
- 2014-06-06 CA CA2917344A patent/CA2917344C/en active Active
- 2014-06-06 KR KR1020167000291A patent/KR102313515B1/ko active Active
- 2014-06-06 PL PL14808115T patent/PL3003039T3/pl unknown
- 2014-06-06 EP EP14808115.1A patent/EP3003039B1/en active Active
- 2014-06-06 LT LTEP14808115.1T patent/LT3003039T/lt unknown
- 2014-06-06 EP EP21150054.1A patent/EP3845529A1/en active Pending
- 2014-06-06 SI SI201431823T patent/SI3003039T1/sl unknown
- 2014-06-06 ES ES14808115T patent/ES2869048T3/es active Active
- 2014-06-06 HR HRP20210813TT patent/HRP20210813T1/hr unknown
- 2014-06-06 HU HUE14808115A patent/HUE054178T2/hu unknown
- 2014-06-06 SM SM20210117T patent/SMT202100117T1/it unknown
- 2014-06-06 WO PCT/US2014/041381 patent/WO2014197846A1/en not_active Ceased
- 2014-06-06 CN CN201480032278.5A patent/CN105263326B/zh active Active
- 2014-06-06 RS RS20210426A patent/RS61724B1/sr unknown
- 2014-06-06 US US14/298,610 patent/US9115089B2/en active Active
- 2014-06-06 CN CN201810282918.8A patent/CN108478579B/zh active Active
- 2014-06-06 KR KR1020217032643A patent/KR102470598B1/ko active Active
- 2014-06-06 KR KR1020227039952A patent/KR102653785B1/ko active Active
- 2014-06-06 JP JP2016518047A patent/JP6699909B2/ja active Active
- 2014-06-06 PT PT148081151T patent/PT3003039T/pt unknown
- 2014-06-06 DK DK14808115.1T patent/DK3003039T3/da active
2015
- 2015-08-07 US US14/821,396 patent/US9636333B2/en active Active
2020
- 2020-01-15 JP JP2020004547A patent/JP6838796B2/ja active Active
2021
- 2021-02-08 JP JP2021018583A patent/JP7146968B2/ja active Active
- 2021-03-31 CY CY20211100281T patent/CY1124222T1/el unknown
2022
- 2022-09-21 JP JP2022150254A patent/JP2022180524A/ja active Pending

Also Published As

Publication number	Publication date
HUE054178T2 (hu)	2021-08-30
ES2869048T3 (es)	2021-10-22
US20140364442A1 (en)	2014-12-11
RS61724B1 (sr)	2021-05-31
KR102470598B1 (ko)	2022-11-23
JP2020075930A (ja)	2020-05-21
SI3003039T1 (sl)	2021-08-31
EP3003039B1 (en)	2021-02-24
LT3003039T (lt)	2021-05-10
PT3003039T (pt)	2021-03-04
CN108478579A (zh)	2018-09-04
US9115089B2 (en)	2015-08-25
WO2014197846A1 (en)	2014-12-11
JP6699909B2 (ja)	2020-05-27
EP3003039A1 (en)	2016-04-13
CN108478579B (zh)	2021-05-25
CA2917344C (en)	2021-09-07
US20150352092A1 (en)	2015-12-10
CN105263326A (zh)	2016-01-20
KR20160017073A (ko)	2016-02-15
KR102653785B1 (ko)	2024-04-01
US9636333B2 (en)	2017-05-02
SMT202100117T1 (it)	2021-05-07
JP6838796B2 (ja)	2021-03-03
CN105263326B (zh)	2018-06-22
CA2917344A1 (en)	2014-12-11
CY1124222T1 (el)	2022-05-27
EP3845529A1 (en)	2021-07-07
JP2021073302A (ja)	2021-05-13
DK3003039T3 (da)	2021-05-25
KR102313515B1 (ko)	2021-10-14
HRP20210813T1 (hr)	2021-06-25
JP2022180524A (ja)	2022-12-06
JP2016520654A (ja)	2016-07-14
KR20220158853A (ko)	2022-12-01
JP7146968B2 (ja)	2022-10-04
KR20210126158A (ko)	2021-10-19
EP3003039A4 (en)	2017-04-19

Publication	Publication Date	Title
IL274355B (en)	2021-02-28	Aza-pyridone compounds and their uses
SMT202100117T1 (it)	2021-05-07	Composti piridinone-piridinile sostituiti con metil/fluoro-piridinil-metossi e composti piridinone-piridinile sostituiti con fluoro-pirimidinil-metossi
ZA201602220B (en)	2018-05-30	Heterocyclic compounds and uses thereof
IL243420A0 (en)	2016-02-29	Heterocyclic compounds and their uses
ZA201506434B (en)	2019-09-25	Heterocyclic compounds and uses thereof
GB201309085D0 (en)	2013-07-03	Compounds
GB201323008D0 (en)	2014-02-12	Compounds and uses thereof
AP2015008713A0 (en)	2015-09-30	Tetrahydropyrrolothiazine compounds
GB201302927D0 (en)	2013-04-03	Compounds
GB201309508D0 (en)	2013-07-10	Compounds
GB201312318D0 (en)	2013-08-21	Novel methods and compounds
SG11201510391VA (en)	2016-01-28	Substituted pyrazolo-pyridinamines
AP3850A (en)	2016-09-30	Azetidinyloxyphenylpyrrolidine compounds
GB201307233D0 (en)	2013-05-29	Compounds and uses thereof
GB201309180D0 (en)	2013-07-03	Compounds and Their Uses
EP2948457A4 (en)	2016-09-07	COMPOUNDS
GB201314610D0 (en)	2013-10-02	Compounds and their uses
GB201306248D0 (en)	2013-05-22	Compounds and their uses
GB201306794D0 (en)	2013-05-29	Compounds
GB201323005D0 (en)	2014-02-12	Compounds and uses thereof
GB201307201D0 (en)	2013-05-29	New compounds and uses
GB201307202D0 (en)	2013-05-29	New compounds and uses
GB201301734D0 (en)	2013-03-20	New compounds and uses
GB201309248D0 (en)	2013-07-03	Compounds and combinations
GB201320161D0 (en)	2014-01-01	Compounds and their uses